FORUM Pharmaceuticals Inc

Quick facts

Phase 2 pipeline

• EVP-0962
• FRM-0334

Phase 1 pipeline

• Antipsychotic therapy · Neurology
  Antagonizes dopamine D2 receptors
• Drug: EVP-6308
• EVP-6308
• Experimental: EVP-6124

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• FORUM Pharmaceuticals Inc portfolio CI brief
• FORUM Pharmaceuticals Inc pipeline updates RSS